Adaptimmune Therapeutics plc's (NASDAQ:ADAP) top owners are individual investors with 39% stake, while 28% is held by institutions [Yahoo! Finance]
Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Last adaptimmune therapeutics plc - american depositary shares earnings: 5/9 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.adaptimmune.com/phoenix.zhtml?c=253991&p=irol-newsarticle&id=2255800
Company Research
Source: Yahoo! Finance
The considerable ownership by individual investors in Adaptimmune Therapeutics indicates that they collectively have a greater say in management and business strategy 52% of the business is held by the top 8 shareholders To get a sense of who is truly in control of Adaptimmune Therapeutics plc ( NASDAQ:ADAP ), it is important to understand the ownership structure of the business. With 39% stake, individual investors possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Meanwhile, institutions make up 28% of the company's shareholders. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Let's delve deeper into each type of owner of Adaptimmune Therapeutics, beginning with the chart below. What Does The Institutional Ownership Tell Us About Adaptimmune Therapeutics? Many institutions measure the
Show less
Read more
Impact Snapshot
Event Time:
ADAP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADAP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADAP alerts
High impacting Adaptimmune Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ADAP
News
- Unlock the Full Potential of Cell and Gene Therapies: The 2024 GenScript Biotech Global Forum Heads to LondonPR Newswire
- Adaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years ago [Yahoo! Finance]Yahoo! Finance
- Medigene AG (MDGEF) Q2 2024 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) was upgraded by analysts at StockNews.com from a "hold" rating to a "strong-buy" rating.MarketBeat
- Adaptimmune Therapeutics plc (NASDAQ: ADAP) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
ADAP
Sec Filings
- 9/23/24 - Form 8-K
- 8/12/24 - Form 10-Q
- 8/12/24 - Form 8-K
- ADAP's page on the SEC website